BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 25271736)

  • 41. Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancer.
    Yang ES; Maiorino CA; Roos BA; Knight SR; Burnstein KL
    Mol Cell Endocrinol; 2002 Jan; 186(1):69-79. PubMed ID: 11850123
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PI3K/Akt signaling regulates p27(kip1) expression via Skp2 in PC3 and DU145 prostate cancer cells, but is not a major factor in p27(kip1) regulation in LNCaP and PC346 cells.
    van Duijn PW; Trapman J
    Prostate; 2006 May; 66(7):749-60. PubMed ID: 16425184
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
    Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
    Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity.
    Siu SW; Lau KW; Tam PC; Shiu SY
    Prostate; 2002 Jul; 52(2):106-22. PubMed ID: 12111702
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oncostatin M induces growth arrest by inhibition of Skp2, Cks1, and cyclin A expression and induced p21 expression.
    Halfter H; Friedrich M; Resch A; Kullmann M; Stögbauer F; Ringelstein EB; Hengst L
    Cancer Res; 2006 Jul; 66(13):6530-9. PubMed ID: 16818624
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neoisoliquiritin exerts tumor suppressive effects on prostate cancer by repressing androgen receptor activity.
    Chen C; Shao R; Li B; Zhai Y; Wang T; Li X; Miao L; Huang J; Liu R; Liu E; Zhu Y; Gao X; Zhang H; Wang Y
    Phytomedicine; 2021 May; 85():153514. PubMed ID: 33676083
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacological inhibition of the SKP2/p300 signaling axis restricts castration-resistant prostate cancer.
    Rezaeian AH; Phan LM; Zhou X; Wei W; Inuzuka H
    Neoplasia; 2023 Apr; 38():100890. PubMed ID: 36871351
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.
    Locke JA; Guns ES; Lubik AA; Adomat HH; Hendy SC; Wood CA; Ettinger SL; Gleave ME; Nelson CC
    Cancer Res; 2008 Aug; 68(15):6407-15. PubMed ID: 18676866
    [TBL] [Abstract][Full Text] [Related]  

  • 49. p27 is regulated independently of Skp2 in the absence of Cdk2.
    Kotoshiba S; Gopinathan L; Pfeiffenberger E; Rahim A; Vardy LA; Nakayama K; Nakayama KI; Kaldis P
    Biochim Biophys Acta; 2014 Feb; 1843(2):436-45. PubMed ID: 24269842
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Galbanic acid decreases androgen receptor abundance and signaling and induces G1 arrest in prostate cancer cells.
    Zhang Y; Kim KH; Zhang W; Guo Y; Kim SH; Lü J
    Int J Cancer; 2012 Jan; 130(1):200-12. PubMed ID: 21328348
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Activation of p53 signaling and inhibition of androgen receptor mediate tanshinone IIA induced G1 arrest in LNCaP prostate cancer cells.
    Won SH; Lee HJ; Jeong SJ; Lü J; Kim SH
    Phytother Res; 2012 May; 26(5):669-74. PubMed ID: 21997969
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer.
    Qi W; Morales C; Cooke LS; Johnson B; Somer B; Mahadevan D
    Oncotarget; 2015 Dec; 6(39):41976-87. PubMed ID: 26506516
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer.
    Urbanucci A; Sahu B; Seppälä J; Larjo A; Latonen LM; Waltering KK; Tammela TL; Vessella RL; Lähdesmäki H; Jänne OA; Visakorpi T
    Oncogene; 2012 Apr; 31(17):2153-63. PubMed ID: 21909140
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Involvement of p27Kip1 in G1 arrest by high dose 5 alpha-dihydrotestosterone in LNCaP human prostate cancer cells.
    Tsihlias J; Zhang W; Bhattacharya N; Flanagan M; Klotz L; Slingerland J
    Oncogene; 2000 Feb; 19(5):670-9. PubMed ID: 10698512
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Skp2 and Slug Are Coexpressed in Aggressive Prostate Cancer and Inhibited by Neddylation Blockade.
    Mickova A; Kharaishvili G; Kurfurstova D; Gachechiladze M; Kral M; Vacek O; Pokryvkova B; Mistrik M; Soucek K; Bouchal J
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799604
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cholestane-3β, 5α, 6β-triol suppresses proliferation, migration, and invasion of human prostate cancer cells.
    Lin CY; Huo C; Kuo LK; Hiipakka RA; Jones RB; Lin HP; Hung Y; Su LC; Tseng JC; Kuo YY; Wang YL; Fukui Y; Kao YH; Kokontis JM; Yeh CC; Chen L; Yang SD; Fu HH; Chen YW; Tsai KK; Chang JY; Chuu CP
    PLoS One; 2013; 8(6):e65734. PubMed ID: 23785446
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Peroxisome proliferator-activated receptor gamma coactivator-1alpha interacts with the androgen receptor (AR) and promotes prostate cancer cell growth by activating the AR.
    Shiota M; Yokomizo A; Tada Y; Inokuchi J; Tatsugami K; Kuroiwa K; Uchiumi T; Fujimoto N; Seki N; Naito S
    Mol Endocrinol; 2010 Jan; 24(1):114-27. PubMed ID: 19884383
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Downregulation of Skp2 and p27/Kip1 synergistically induces apoptosis in T98G glioblastoma cells.
    Lee SH; McCormick F
    J Mol Med (Berl); 2005 Apr; 83(4):296-307. PubMed ID: 15605273
    [TBL] [Abstract][Full Text] [Related]  

  • 59. p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells.
    Roy S; Kaur M; Agarwal C; Tecklenburg M; Sclafani RA; Agarwal R
    Mol Cancer Ther; 2007 Oct; 6(10):2696-707. PubMed ID: 17938263
    [TBL] [Abstract][Full Text] [Related]  

  • 60. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
    Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
    Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.